BTNL2: A Nucleotide-Laced Protein Involved in Cancer and Brain Function

Target Name: BTNL2

NCBI ID: G56244

BTNL2

BTNL2: A Nucleotide-Laced Protein Involved in Cancer and Brain Function

BTNL2 (Brain-Tumor Nucleotide-Laced 2) is a protein that is expressed in various tissues of the brain, including neurons, glial cells, and blood vessels. It is a nucleotide-laced protein, which means that it is composed of a nucleotide sequence that is repeated multiple times. The most common nucleotide used in BTNL2 is GCTC, which stands for GuanosineCGCTC.

BTNL2 is a protein that has been shown to play a role in the development and progression of various types of cancer, particularly brain tumors. It is often used as a biomarker to assess the effectiveness of anti-cancer drugs in these tumors. In addition, BTNL2 has also been shown to be involved in the regulation of cell survival and the development of neurodegenerative diseases.

BTNL2 is expressed in various tissues of the brain, including neurons, glial cells, and blood vessels. It is primarily expressed in the peri-glial layer of the brain, which is the layer of cells that surround the neurons and glial cells. This layer is thought to be a key site for the development and progression of BTNL2-positive tumors.

BTNL2 is a protein that is involved in the regulation of various cellular processes that are important for brain function. For example, it is known to be involved in the regulation of cell proliferation, cell survival, and neurotransmitter release. It is also thought to play a role in the regulation of the blood-brain barrier, which is the barrier that separates the brain from the bloodstream.

BTNL2 has been shown to be involved in the development and progression of various types of cancer, particularly brain tumors. For example, it has been shown to be involved in the development of glioblastoma, a type of brain tumor that is characterized by the rapid growth and progression of cells. In addition, BTNL2 has also been shown to be involved in the development of other types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its role in the development and progression of cancer, BTNL2 is also thought to be involved in the regulation of various cellular processes that are important for brain function. For example, it is known to be involved in the regulation of cell proliferation, cell survival, and neurotransmitter release. It is also thought to play a role in the regulation of the blood-brain barrier, which is the barrier that separates the brain from the bloodstream.

BTNL2 is a protein that has been shown to be involved in the development and progression of various types of cancer, particularly brain tumors. It is often used as a biomarker to assess the effectiveness of anti-cancer drugs in these tumors. In addition, BTNL2 has also been shown to be involved in the regulation of cell survival and the development of neurodegenerative diseases. Further research is needed to fully understand the role of BTNL2 in these processes.

Protein Name: Butyrophilin Like 2

Functions: Negative regulator of T-cell proliferation

The "BTNL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTNL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets